Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	.C. 20549
---------------	-----------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar STEPH (Last) C/O BRI 421 KIPI	Suer Name and Ticker or Trading Symbol     BridgeBio Pharma, Inc. [ BBIO ]      Date of Earliest Transaction (Month/Day/Year)     04/01/2020  4. If Amendment, Date of Original Filed (Month/Day/Year)										X S. Indiv	all app Direct Office below	licable) tor er (give title v) See Ro	10% Ow Other (s below) Remarks		wner specify				
(Street) PALO ALTO CA 94301																X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(Sta	ate) (Z	Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transactio Date (Month/Day/N					ear)   E	2A. Deemed Execution Date if any (Month/Day/Yea		, T	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			5)	5. Amount of Securities Beneficially Owned Following Reported				7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								c	Code V		Am	nount	(A) or (D)	Price	Trans		action(s) 3 and 4)	(	,	(
Common Stock 04/01					.0				S <sup>(1)</sup>		3	3,414	D	\$26.00	57 <sup>(2)</sup> 334,		34,102		D	
Common Stock 04/01/2				04/01/202	0				S <sup>(1)</sup>		2	2,500	D	\$26.85	96 <sup>(3)</sup>	331,602			D	
Common Stock 04/0				04/01/202	20				S <sup>(1)</sup>		1	1,286	D	\$27.74	27.7427(4)		330,316		D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	Derivative Security Price of Derivative Security  Security  Onversion or Exercise (Month/Day/Year)  Price of Derivative Security  Date (Month/Day/Year)  Execution Date, if any (Month/Day/Year)  Execution Date, if any (Month/Day/Year)  Execution Date, if any (Month/Day/Year)					saction (Instr.	5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr and 5	rities ired sed	Expiration Date			Amo Secu Unde Deriv Secu 3 and	le and unt of rities strlying rative rity (Instr. i 4)  Amount or Number of Shares	nt er		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

## **Explanation of Responses:**

- 1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019.
- 2. Represents the weighted average sale price of the shares sold from \$25.43 to \$26.41 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4.
- 3. Represents the weighted average sale price of the shares sold from \$26.44 to \$27.42 per share.
- 4. Represents the weighted average sale price of the shares sold from \$27.50 to \$28.18 per share.

## Remarks:

Secretary, Treasurer and Chief Financial Officer

/s/ Tara Condon, Attorney-in-

**Fact** 

\*\* Signature of Reporting Person Date

04/03/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.